Celltrion says a standardized, globally-accepted approach to ‘biobetters’ – biosimilars that offer improvements over the original reference biologic – is needed to reduce unnecessary trial duplication and allow biobetter products to come to market more quickly, following mixed experiences internationally with registering its Remsima SC subcutaneous version of biosimilar infliximab.
Remsima SC was based on Remicade, but offered a unique subcutaneous route of administration that meant that it could not...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?